OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
JULPHAR.AD60

Gulf Pharmaceutical Industries Julphar Co PJSC

PharmaceuticalsVerified

Julphar maintains a conservative capital structure with a debt-to-equity ratio of 0.29, indicating a relatively low reliance on debt financing. The company's liquidity position is reflected in a current ratio of 3.12, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 18.14% and a return on assets (ROA) of 9.68%, both of which are strong indicators of efficient capital utilization and asset management. These figures suggest that Julphar is generating solid returns for its shareholders and effectively deploying its assets to generate income. The company operates through three main segments: Manufacturing, Planet, and Investments. While the input data does not provide specific revenue breakdowns by segment, the disclosed segments indicate a diversified business model. The geographic exposure is primarily concentrated in the United Arab Emirates, with no additional international revenue details provided in the input data. Looking at the growth trajectory, the input data does not include forward-looking revenue projections or outlooks for the current or next fiscal year. However, the company's operating income of AED 63.7 million and net income of AED 172.2 million suggest a stable earnings base. The capital expenditure of AED -46 million indicates a reduction in investment in physical assets, which may reflect a shift in strategic focus or a response to market conditions. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's liquidity risk is partially attributed to the negative net cash position after accounting for total debt. The dilution risk is low, and no dilution sources are explicitly identified in the input data. The company has not made any adjustments to its valuation metrics that would suggest a significant change in its capital structure or earnings potential. Recent events and filings do not appear to be detailed in the input data. The company's financial snapshot does not include specific references to recent earnings calls, 10-K filings, or other disclosures that would provide insight into management commentary or strategic direction. The absence of such information limits the ability to assess recent developments that may impact the company's performance.

30-day price · JULPHAR.AD+0.08 (+8.0%)
Low$0.99High$1.15Close$1.08As of17 May, 00:00 UTC
Profile
CompanyGulf Pharmaceutical Industries Julphar Co PJSC
TickerJULPHAR.AD
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Gulf Pharmaceutical Industries Julphar Co PJSC (JULPHAR.AD) is a United Arab Emirates-based pharmaceutical company that engages in the manufacturing and sale of medicines, drugs, and various pharmaceutical and medical compounds, including general medicines, diabetes solutions, cardiovascular care, consumer healthcare products, wound care and dermatology, and respiratory and GIT medicines.

Classification. Julphar is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry, with a classification confidence of 0.92.

Julphar maintains a conservative capital structure with a debt-to-equity ratio of 0.29, indicating a relatively low reliance on debt financing. The company's liquidity position is reflected in a current ratio of 3.12, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 18.14% and a return on assets (ROA) of 9.68%, both of which are strong indicators of efficient capital utilization and asset management. These figures suggest that Julphar is generating solid returns for its shareholders and effectively deploying its assets to generate income. The company operates through three main segments: Manufacturing, Planet, and Investments. While the input data does not provide specific revenue breakdowns by segment, the disclosed segments indicate a diversified business model. The geographic exposure is primarily concentrated in the United Arab Emirates, with no additional international revenue details provided in the input data. Looking at the growth trajectory, the input data does not include forward-looking revenue projections or outlooks for the current or next fiscal year. However, the company's operating income of AED 63.7 million and net income of AED 172.2 million suggest a stable earnings base. The capital expenditure of AED -46 million indicates a reduction in investment in physical assets, which may reflect a shift in strategic focus or a response to market conditions. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's liquidity risk is partially attributed to the negative net cash position after accounting for total debt. The dilution risk is low, and no dilution sources are explicitly identified in the input data. The company has not made any adjustments to its valuation metrics that would suggest a significant change in its capital structure or earnings potential. Recent events and filings do not appear to be detailed in the input data. The company's financial snapshot does not include specific references to recent earnings calls, 10-K filings, or other disclosures that would provide insight into management commentary or strategic direction. The absence of such information limits the ability to assess recent developments that may impact the company's performance.
Key takeaways
  • Julphar maintains a strong ROE of 18.14% and ROA of 9.68%, indicating efficient capital and asset utilization.
  • The company's debt-to-equity ratio of 0.29 suggests a conservative capital structure with limited leverage.
  • The current ratio of 3.12 indicates a solid short-term liquidity position, though the risk assessment notes a negative net cash position after subtracting total debt.
  • The company operates through three segments: Manufacturing, Planet, and Investments, with no detailed revenue breakdowns provided.
  • Analysts have issued one sell recommendation, with no strong buy or buy recommendations, suggesting a cautious outlook.
  • The company's capital expenditure is negative, indicating a reduction in investment in physical assets.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyAED
Revenue$1.08B
Gross profit$435.9M
Operating income$63.7M
Net income$172.2M
R&D
SG&A
D&A
SBC
Operating cash flow$120.9M
CapEx-$46.0M
Free cash flow$55.9M
Total assets$1.78B
Total liabilities$830.7M
Total equity$949.1M
Cash & equivalents
Long-term debt$275.0M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$949.1M
Net cash-$275.0M
Current ratio3.1
Debt/Equity0.3
ROA9.7%
ROE18.1%
Cash conversion70.0%
CapEx/Revenue-4.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
MetricJULPHAR.ADActivity
Op margin5.9%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin16.0%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin40.5%47.8% medp25 27.6% · p75 68.9%below median
CapEx / revenue-4.3%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity29.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
Mean recommendation4.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count0.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate0.02 AED
Last actual EPS0.15 AED
Mean revenue estimate1,112,000,000 AED
Last actual revenue1,075,500,000 AED
Mean EBIT estimate95,800,000 AED
market data ESG controversies score100.0
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 13:27 UTC#c592188a
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 13:28 UTCJob: 7319ab4c